
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd Inc is positioned favorably within the clinical-stage biopharmaceutical sector, particularly with its development of antibodies aimed at infectious diseases, most notably COVID-19. The company has secured FDA approval for its Phase 3 program (REVOLUTION) for VYD2311, which could significantly expand its potential market by demonstrating superiority over existing mRNA vaccines. Additionally, the increasing global market for antibody treatments, projected to reach $3-4 billion by 2030, combined with the product candidates' innovative technologies, underpins a positive outlook for the company's financial prospects and market competitiveness.
Bears say
Invivyd Inc. is facing significant challenges, as evidenced by a misleading in silico modeling result that revealed a dramatic 200-fold decrease in the efficacy of its lead product candidate, ADG20, against the omicron variant during the STAMP trial. Compounding this issue, the overall market opportunity has diminished, with declining vaccination rates for COVID-19 and influenza, particularly among vulnerable populations such as the elderly and immunocompromised, who require effective solutions the most. Amidst concerns of vaccine hesitancy and a shrinking target demographic, the viability and commercial prospects of Invivyd's antibody-based therapies appear increasingly compromised.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares